Browse by Medical Category
Clinical Trials at CURTIS
Find targeted therapy trials for melanoma
The Melanoma Center and Pigmented Lesion Center (PLC) at Massachusetts General Hospital has been at the forefront of cutaneous melanoma research and melanoma patient care for over 40 years.
The PLC provides a one-stop-shop approach to treating melanoma and handles all aspects of care required by early-stage patients.
During an initial consultation, the patient's moles and skin lesions are examined by a team that includes a dermatologist, a cancer surgeon and a melanoma pathologist. Our multidisciplinary team then works together to quickly diagnose the precise condition and map out the most effective treatment. If the disease has spread to other sites, amedical oncologistmight join our team as well.
We have a high-risk unit that focuses on the initial surgical treatment and the first five years of postmelanoma surveillance. Once patients have passed this early often difficult period, we also have a lower-risk “step down” unit that continues the surveillance for up to 10 years. Patients at extreme risk for melanoma because of genetic factors may remain within our care past the 10-year period. During all follow-up visits, we continually reinforce melanoma education and prevention.
As part of theMass General Melanoma Center,we regularly interact with surgical, medical and radiation oncologists who specialize in melanoma management. We direct patients with advanced-stage melanoma to these specialists when necessary.
Because the link between family history and cancer has been well established, we place special emphasis on genetic counseling. In fact, we have led the way in integrating this component of melanoma treatment. With over 200 melanoma-prone families from all over the world participating in our research efforts, we are making steady progress towards understanding the fundamental causes of melanoma.
Moreover, our patients have the opportunity to examine not just the disease they have, but whether they might pass on this disease to the next generation.
The PLC is deeply committed to achieving breakthroughs in melanoma research. As a research unit, our investigators were among the first to describe:
In addition, our laboratory has been heavily involved in "dismantling" the melanoma engine that drives tumor progression. Through the years, we have shown various patterns of mutations that occur in the tumor, leading to melanoma growth.
Incorporating the Latest Technology
The PLC collaborates with scientists in computer science, artificial intelligence, imaging technology and more to define better methods for detecting melanoma.
The Melanoma Center and Pigmented Lesion CenterMassachusetts General Hospital50 Staniford Street, Suite 200Boston, MA 02114617-724-6082
Our center was established in 1966 to advance understanding of cutaneous melanoma, a relatively rare cancer at the time. The incidence of this disease has since risen dramatically, and we have become one of the major centers for melanoma patient care in New England and a leader in all aspects of melanoma investigation.
Hensin Tsao, MD, PhD, a respected expert in the field, has served as our director since 2005. The multidisciplinary PLC staff includes:
The PLC team offers outside physicians and dermatologists consultative services for moles and melanoma. Each year, we evaluate over 200 new melanoma patients and host over 3,000 visits. The experience we gain in handling large numbers of cases improves outcomes for all of our patients.
Our team is interested in heredity's role in melanoma risk as well as how changes in DNA dictate the growth of melanoma tumors and their sensitivity to therapy. We are particularly interested in families with melanoma, because cancers in the familial setting often provide clues to their origin.
Currently, we are enrolling melanoma patients with a family history in a large cancer-risk trial. The potential benefits from a clearer understanding of melanoma at the genetic level are limitless. Contact us to learn more about participating.
Melanoma is a disease of the skin in which cancer cells are found in the melanocytes, the cells that produce color in the skin or pigment known as melanin.
As a person grows older and is exposed to sunlight, the skin changes. Most people have some skin marks, such as freckles and moles, which may multiply or darken over time.
Skin cancer is a malignant tumor that grows in the skin cells and accounts for more than 50 percent of all cancers.
Skin color is determined by a pigment (melanin) made by specialized cells in the skin (melanocytes). Some disorders which affect skin color are: albinism, melasma, pigment loss after skin damage, and vitiligo.
Hensin Tsao, MD, Director of Mass General's Melanoma and Pigmented Lesion Center explains how family history, genetic risks and personal health history can all affect your risk of melanoma, and what steps you should take to detect it at an early, treatable stage.
The Melanoma Center and Pigmented Lesion Center
Massachusetts General Hospital
Back to Top